At least in the mouse model, the peptide-based drugs against S100A4 have a potential as a novel antiangiogenic therapeutic agent, which is involved in starvation tactics-type anticancer drugs pioneered by Folkman,45 for both S100A4-positive cancers and -negative cancers. The gene discussed is S100A4; the disease is cancer.